{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"groupId":"OG001","spread":"88.318","value":"54.26"},{"groupId":"OG002","spread":"0","value":"0"},{"groupId":"OG003","spread":"42.971","value":"-20.27"},{"groupId":"OG004","spread":"15.707","value":"-74.87"},{"groupId":"OG005","spread":"82.394","value":"-13.32"},{"groupId":"OG006","spread":"0","value":"0"},{"groupId":"OG007","spread":"3.057","value":"-81.57"},{"groupId":"OG008","spread":"39.141","value":"-61.96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"4"}],"units":"Participants"}],"description":"The dose dependent change in a mitogen-activated protein kinases (MAPK) pathway expression signature was analyzed for all available samples of MTC and NSCLC participants. Participants with archived sample (used as baseline) and on treatment Cycle 2 Day 1 (1 cycle = 28 days) tumor tissues with greater than 20% tumor cells are included in the analysis. The changes in tumor biomarker DUSP6 levels was explored.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received pralsetinib 30 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG000","title":"Phase I: Pralsetinib 30 mg"},{"description":"Participants received pralsetinib 60 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG001","title":"Phase I: Pralsetinib 60 mg"},{"description":"Participants received pralsetinib 100 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG002","title":"Phase I: Pralsetinib 100 mg"},{"description":"Participants received pralsetinib 200 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG003","title":"Phase I: Pralsetinib 200 mg"},{"description":"Participants received pralsetinib 300 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG004","title":"Phase I: Pralsetinib 300 mg"},{"description":"Participants received pralsetinib 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG005","title":"Phase I: Pralsetinib 400 mg"},{"description":"Participants received pralsetinib 600 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG006","title":"Phase I: Pralsetinib 600 mg"},{"description":"Participants received pralsetinib 100 mg, orally, BID until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG007","title":"Phase I: Pralsetinib 100/100 mg"},{"description":"Participants received pralsetinib 200 mg in the morning and then 100 mg in the evening orally until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG008","title":"Phase I: Pralsetinib 200/100 mg"}],"paramType":"MEAN","populationDescription":"Safety Population included all participants who have received at least 1 dose of the study drug regardless of starting dose levels.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 4","title":"Phase 1: Percent Change From Baseline in Dual Specificity Phosphatase 6 (DUSP6)","type":"SECONDARY","unitOfMeasure":"percent change"}